account_balance
Investment manager · 13F filer · SEC CIK 1802528
Fairmount Funds Management LLC
Reported value$1.51Bas of Jun 30, 2026
Positions12 1 new, 1 sold out
Top 10 weight97.6%ORKA alone is 23%
FiledAug 1445 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
This fund reports 12 stocks.
ORKAOruka Therapeutics Inc
23.3%
DNTHDianthus Therapeutics Inc
16.3%
DMRADamora Therapeutics Inc
15.0%
COGTCogent Biosciences Inc
14.1%
JBIOJade Biosciences Inc
6.7%
ELVNEnliven Therapeutics Inc
6.2%
VRDNViridian Therapeutics Inc
6.2%Added +30%
ZBIOZenas Biopharma Inc
4.0%
CBIOCrescent Biopharma Inc.
3.3%
APGE2.6%
FTH1.2%IKT1.2%ORKAOruka Therapeutics Inc
23.3%
DNTHDianthus Therapeutics Inc
16.3%
DMRADamora Therapeutics Inc
15.0%
COGTCogent Biosciences Inc
14.1%
JBIO6.7%ELVN6.2%VRDN6.2%ZBIO4.0%CBIO3.3%APGE2.6%
FTHIKTBox size is the share of the fund. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 12 as a list
ORKA Oruka Therapeutics Inc 23.3% HeldDNTH Dianthus Therapeutics Inc 16.3% HeldDMRA Damora Therapeutics Inc 15.0% HeldCOGT Cogent Biosciences Inc 14.1% HeldJBIO Jade Biosciences Inc 6.7% HeldELVN Enliven Therapeutics Inc 6.2% HeldVRDN Viridian Therapeutics Inc 6.2% Added +30%ZBIO Zenas Biopharma Inc 4.0% HeldCBIO Crescent Biopharma Inc. 3.3% Held
APGE Apogee Therapeutics Inc 2.6% Held
FTH Faeth Therapeutics Inc 1.2% NewIKT Inhibikase Therapeutics Inc 1.2% HeldWhat changed